The Complex Journey of a Vaccine – The Steps Behind Developing a New Vaccine
Read more2nd global Biopharma CEO / top execs virtual press briefing – COVID-19
IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D. The briefing was an opportunity to hear directly from the decision-makers.
Read moreMomentum of COVID-19 vaccine manufacturing scale up sufficient for step change in distribution
This month COVID-19 vaccine manufacturing output will pass the 7.5 billion dose mark. Vaccine manufacturers worldwide are now producing 1.5 billion doses per month and this is expected to continue growing. 12 billion vaccines will be produced by the end of 2021 and if there are no major bottlenecks, by June 2022 total vaccine production...
Read more4th global Biopharma CEO / top execs virtual press briefing – COVID-19
IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D.
Read moreChallenges and solutions to scaling-up COVID-19 vaccine manufacturing capacity
On the first anniversary of the Access to COVID-19 Tools Accelerator (ACT Accelerator), high-level representatives – from pharma and biotech trade associations and vaccine manufacturers from both developed and developing countries – met to discuss the challenges of scaling-up vaccine production and ensuring vaccine equity. Present at the meeting were IFPMA Director General Thomas Cueni,...
Read moreRich countries must pay more to achieve health for all in poorer countries
This article was originally published in the Financial Times on October 30, 2019. Rich countries must pay more to achieve health for all in poorer countries Trade association chief argues the case for differentiated pricing If you live on as little as $2 a day, even finding 20 cents for a blood test, a hospital...
Read more1st global Biopharma CEO / top execs virtual press briefing – COVID-19
IFPMA organized a virtual press briefing with CEOs and top executives who are at the forefront of biopharmaceutical R&D. The briefing was an opportunity to hear directly from the decision-makers.
Read moreThe Biopharmaceutical Industry’s Three Priorities to Urgently Increase COVID-19 Vaccine Access
As the focus of the global COVID-19 pandemic response shifts downstream from the development and production of vaccines to vaccination campaigns themselves, IFPMA Director-General Thomas Cueni lays out the biopharmaceutical industry’s three new overarching priorities.
Read moreAccess to antiretrovirals in developing countries: towards a new landscape?
Read moreInterview – BBC World Business Report – Will a coronavirus vaccine reach the developing world?
The biopharmaceutical industry has made addressing the pandemic its top priority, devoting its resources, expertise, know-how, and intellectual assets to developing potential treatments and vaccines at record speed, while committing to and engaging in unprecedented levels of international collaboration and coordination through initiatives such as ACT-A, ACTIV and CEPI to ensure equitable access to products being developed. Thomas Cueni, Director General of...
Read more